Pharmaceutical CDMO (Contract Development and Manufacturing Organization) solutions refer to the services offered by companies that provide end-to-end outsourcing services to the pharmaceutical industry. CDMOs partner with pharmaceutical companies to assist in various stages of drug development, from early-stage research and development (R&D) to commercial-scale manufacturing and distribution.
The global Pharmaceutical CDMO Solution market is projected to reach US$ 215590 million in 2029, increasing from US$ 128270 million in 2022, with the CAGR of 7.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical CDMO Solution market research.
The pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry has experienced significant growth and transformation in recent years. CDMOs play a crucial role in supporting pharmaceutical companies by providing a wide range of services to expedite drug development and manufacturing processes. Pharmaceutical companies increasingly rely on CDMOs to access specialized expertise, advanced technologies, and cost-effective solutions, enabling them to focus on core research and marketing activities. The rising complexity of drug development, along with increasing regulatory requirements, has led to a higher demand for CDMO services, particularly in specialized areas like biologics, gene therapies, and personalized medicine. The United States and Canada are significant markets for pharmaceutical CDMOs due to a large number of biopharmaceutical companies and a robust outsourcing landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to a strong demand for CDMO services. Countries like India, China, and South Korea have emerged as major players in the CDMO market, offering cost-competitive services and advanced manufacturing capabilities. The global market for pharmaceutical CDMO solutions is expected to witness continued growth in the coming years, driven by increased outsourcing by pharmaceutical companies seeking specialized expertise, cost-effectiveness, and accelerated drug development timelines. Additionally, the ongoing advancements in biotechnology, gene therapies, and personalized medicine are likely to create new opportunities for CDMOs, as these cutting-edge areas require specialized capabilities and infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmaceutical CDMO Solution market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Recipharm AB
Lonza Group
Catalent
Patheon (Thermo Fisher Scientific)
Siegfried AG
SGS Quay Pharmaceuticals
Curia
Thermo Fisher Scientific
Samsung Biologics
Fujifilm Diosynth Biotechnologies
Societal CDMO
Aenova Group
Eurofins CDMO
Piramal Group
WuXi AppTec Group
Fareva
Strides Pharma Science
Famar Health Care Service
WuXi Biologics
Asymchem
Pfizer CentreOne
Segment by Type
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development and Manufacturing
Secondary Packaging
Others
Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical CDMO Solution report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharmaceutical CDMO Solution 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Active Pharmaceutical Ingredient (API) Manufacturing
1.2.3 Finished Dosage Formulation (FDF) Development and Manufacturing
1.2.4 Secondary Packaging
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Pharmaceutical CDMO Solution 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Solution 麻豆原创 Perspective (2018-2029)
2.2 Pharmaceutical CDMO Solution Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Solution 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceutical CDMO Solution Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Pharmaceutical CDMO Solution Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Pharmaceutical CDMO Solution 麻豆原创 Dynamics
2.3.1 Pharmaceutical CDMO Solution Industry Trends
2.3.2 Pharmaceutical CDMO Solution 麻豆原创 Drivers
2.3.3 Pharmaceutical CDMO Solution 麻豆原创 Challenges
2.3.4 Pharmaceutical CDMO Solution 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Solution Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Solution Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical CDMO Solution Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Pharmaceutical CDMO Solution 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CDMO Solution Revenue
3.4 Global Pharmaceutical CDMO Solution 麻豆原创 Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Solution 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Solution Revenue in 2022
3.5 Pharmaceutical CDMO Solution Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CDMO Solution Product Solution and Service
3.7 Date of Enter into Pharmaceutical CDMO Solution 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Solution Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Solution Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Pharmaceutical CDMO Solution Forecasted 麻豆原创 Size by Type (2024-2029)
5 Pharmaceutical CDMO Solution Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Solution Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Pharmaceutical CDMO Solution Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical CDMO Solution 麻豆原创 Size (2018-2029)
6.2 North America Pharmaceutical CDMO Solution 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2018-2023)
6.4 North America Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Solution 麻豆原创 Size (2018-2029)
7.2 Europe Pharmaceutical CDMO Solution 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2018-2023)
7.4 Europe Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Solution 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Pharmaceutical CDMO Solution 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceutical CDMO Solution 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical CDMO Solution 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Solution 麻豆原创 Size (2018-2029)
9.2 Latin America Pharmaceutical CDMO Solution 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Solution 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Pharmaceutical CDMO Solution 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical CDMO Solution 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm AB
11.1.1 Recipharm AB Company Detail
11.1.2 Recipharm AB Business Overview
11.1.3 Recipharm AB Pharmaceutical CDMO Solution Introduction
11.1.4 Recipharm AB Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.1.5 Recipharm AB Recent Development
11.2 Lonza Group
11.2.1 Lonza Group Company Detail
11.2.2 Lonza Group Business Overview
11.2.3 Lonza Group Pharmaceutical CDMO Solution Introduction
11.2.4 Lonza Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.2.5 Lonza Group Recent Development
11.3 Catalent
11.3.1 Catalent Company Detail
11.3.2 Catalent Business Overview
11.3.3 Catalent Pharmaceutical CDMO Solution Introduction
11.3.4 Catalent Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.3.5 Catalent Recent Development
11.4 Patheon (Thermo Fisher Scientific)
11.4.1 Patheon (Thermo Fisher Scientific) Company Detail
11.4.2 Patheon (Thermo Fisher Scientific) Business Overview
11.4.3 Patheon (Thermo Fisher Scientific) Pharmaceutical CDMO Solution Introduction
11.4.4 Patheon (Thermo Fisher Scientific) Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.4.5 Patheon (Thermo Fisher Scientific) Recent Development
11.5 Siegfried AG
11.5.1 Siegfried AG Company Detail
11.5.2 Siegfried AG Business Overview
11.5.3 Siegfried AG Pharmaceutical CDMO Solution Introduction
11.5.4 Siegfried AG Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.5.5 Siegfried AG Recent Development
11.6 SGS Quay Pharmaceuticals
11.6.1 SGS Quay Pharmaceuticals Company Detail
11.6.2 SGS Quay Pharmaceuticals Business Overview
11.6.3 SGS Quay Pharmaceuticals Pharmaceutical CDMO Solution Introduction
11.6.4 SGS Quay Pharmaceuticals Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.6.5 SGS Quay Pharmaceuticals Recent Development
11.7 Curia
11.7.1 Curia Company Detail
11.7.2 Curia Business Overview
11.7.3 Curia Pharmaceutical CDMO Solution Introduction
11.7.4 Curia Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.7.5 Curia Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Pharmaceutical CDMO Solution Introduction
11.8.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Samsung Biologics
11.9.1 Samsung Biologics Company Detail
11.9.2 Samsung Biologics Business Overview
11.9.3 Samsung Biologics Pharmaceutical CDMO Solution Introduction
11.9.4 Samsung Biologics Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.9.5 Samsung Biologics Recent Development
11.10 Fujifilm Diosynth Biotechnologies
11.10.1 Fujifilm Diosynth Biotechnologies Company Detail
11.10.2 Fujifilm Diosynth Biotechnologies Business Overview
11.10.3 Fujifilm Diosynth Biotechnologies Pharmaceutical CDMO Solution Introduction
11.10.4 Fujifilm Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.10.5 Fujifilm Diosynth Biotechnologies Recent Development
11.11 Societal CDMO
11.11.1 Societal CDMO Company Detail
11.11.2 Societal CDMO Business Overview
11.11.3 Societal CDMO Pharmaceutical CDMO Solution Introduction
11.11.4 Societal CDMO Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.11.5 Societal CDMO Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Detail
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Pharmaceutical CDMO Solution Introduction
11.12.4 Aenova Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.12.5 Aenova Group Recent Development
11.13 Eurofins CDMO
11.13.1 Eurofins CDMO Company Detail
11.13.2 Eurofins CDMO Business Overview
11.13.3 Eurofins CDMO Pharmaceutical CDMO Solution Introduction
11.13.4 Eurofins CDMO Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.13.5 Eurofins CDMO Recent Development
11.14 Piramal Group
11.14.1 Piramal Group Company Detail
11.14.2 Piramal Group Business Overview
11.14.3 Piramal Group Pharmaceutical CDMO Solution Introduction
11.14.4 Piramal Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.14.5 Piramal Group Recent Development
11.15 WuXi AppTec Group
11.15.1 WuXi AppTec Group Company Detail
11.15.2 WuXi AppTec Group Business Overview
11.15.3 WuXi AppTec Group Pharmaceutical CDMO Solution Introduction
11.15.4 WuXi AppTec Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.15.5 WuXi AppTec Group Recent Development
11.16 Fareva
11.16.1 Fareva Company Detail
11.16.2 Fareva Business Overview
11.16.3 Fareva Pharmaceutical CDMO Solution Introduction
11.16.4 Fareva Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.16.5 Fareva Recent Development
11.17 Strides Pharma Science
11.17.1 Strides Pharma Science Company Detail
11.17.2 Strides Pharma Science Business Overview
11.17.3 Strides Pharma Science Pharmaceutical CDMO Solution Introduction
11.17.4 Strides Pharma Science Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.17.5 Strides Pharma Science Recent Development
11.18 Famar Health Care Service
11.18.1 Famar Health Care Service Company Detail
11.18.2 Famar Health Care Service Business Overview
11.18.3 Famar Health Care Service Pharmaceutical CDMO Solution Introduction
11.18.4 Famar Health Care Service Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.18.5 Famar Health Care Service Recent Development
11.19 WuXi Biologics
11.19.1 WuXi Biologics Company Detail
11.19.2 WuXi Biologics Business Overview
11.19.3 WuXi Biologics Pharmaceutical CDMO Solution Introduction
11.19.4 WuXi Biologics Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.19.5 WuXi Biologics Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Detail
11.20.2 Asymchem Business Overview
11.20.3 Asymchem Pharmaceutical CDMO Solution Introduction
11.20.4 Asymchem Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.20.5 Asymchem Recent Development
11.21 Pfizer CentreOne
11.21.1 Pfizer CentreOne Company Detail
11.21.2 Pfizer CentreOne Business Overview
11.21.3 Pfizer CentreOne Pharmaceutical CDMO Solution Introduction
11.21.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.21.5 Pfizer CentreOne Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Recipharm AB
Lonza Group
Catalent
Patheon (Thermo Fisher Scientific)
Siegfried AG
SGS Quay Pharmaceuticals
Curia
Thermo Fisher Scientific
Samsung Biologics
Fujifilm Diosynth Biotechnologies
Societal CDMO
Aenova Group
Eurofins CDMO
Piramal Group
WuXi AppTec Group
Fareva
Strides Pharma Science
Famar Health Care Service
WuXi Biologics
Asymchem
Pfizer CentreOne
听
听
*If Applicable.
